Letter on "(1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial"

[...]this concept represents the most clinically sound explanation of the duration of empirical antifungal therapy among controls, in which 45.5% of participants were surgical patients, that are known to be a population at significant risk of IC [7]. [...]BDG-based strategy reduces the risk of inappropriate exposure to empiric antifungal therapy in severe critically ill patients with suspected ICI. [...]BDG clinical performance may be even improved by concurrent and integrated use of biomarkers (e.g. procalcitonin, mannan and anti-mannan serum assays [1, 7,8,, 8]), in order to provide a prompt and objective diagnosis of IC, thus orienting the clinical management of this life-threatening clinical condition. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and